Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Although antibiotic treatment for Lyme disease is effective in the majority of cases, especially during the early phase of the disease, a minority of patients suffer from post-treatment Lyme disease syndrome (PTLDS). It is unclear what mechanisms drive this problem, and although slow or ineffective killing of Borrelia burgdorferi has been suggested as an explanation, there is a lack of evidence that viable organisms are present in PTLDS. Although not a clinical surrogate, insight may be gained by examining stationary-phase in vitro Borrelia burgdorferi persisters that survive treatment with the antibiotics doxycycline and amoxicillin. To identify drug candidates that can eliminate B. burgdorferi persisters more effectively, we screened an Food and Drug Administration (FDA)-approved drug library consisting of 1524 compounds against stationary-phase B. burgdorferi by using a newly developed high throughput SYBR Green I/propidium iodide (PI) assay. We identified 165 agents approved for use in other disease conditions that had more activity than doxycycline and amoxicillin against B. burgdorferi persisters. The top 27 drug candidates from the 165 hits were confirmed to have higher anti-persister activity than the current frontline antibiotics. Among the top 27 confirmed drug candidates from the 165 hits, daptomycin, clofazimine, carbomycin, sulfa drugs (e.g., sulfamethoxazole), and certain cephalosporins (e.g. cefoperazone) had the highest anti-persister activity. In addition, some drug candidates, such as daptomycin and clofazimine (which had the highest activity against non-growing persisters), had relatively poor activity or a high minimal inhibitory concentration (MIC) against growing B. burgdorferi. Our findings may have implications for the development of a more effective treatment for Lyme disease and for the relief of long-term symptoms that afflict some Lyme disease patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pogliano, J., Pogliano, N., & Silverman, J. A. (2012) · Journal of Bacteriology · doi:10.1128/jb.00011-12 · Cited by 319
Cited by
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.34 · Cited by 1,612
Formation, physiology, ecology, evolution and clinical importance of bacterial persisters
Van den Bergh, B., Fauvart, M., & Michiels, J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux001 · Cited by 381
Bacterial persisters: molecular mechanisms and therapeutic development
Niu, H., Gu, J., & Zhang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01866-5 · Cited by 310
Self-citationFeng, J., Weitner, M., Shi, W., Zhang, S., Sullivan, D., & Zhang, Y. (2015) · Antibiotics · doi:10.3390/antibiotics4030397 · Cited by 43
Self-citationLiegner, K. B. (2019) · Antibiotics · doi:10.3390/antibiotics8020072 · Cited by 35
“Several groups of researchers have recently identified novel compounds for Lyme disease treatment [26,36,37].”
BackgroundSaputo, S., Faustoferri, R. C., & Quivey, R. G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01674-17 · Cited by 29
“uses, which can aid in rapid identification of new therapies (19, 23, 25).”
BackgroundKuvaldina, M., Preston, J., McClellan, D., Pavlicova, M., Brannagan, T. H., & Fallon, B. A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1549324 · Cited by 2
Metadata
- Authors
- Feng, J., Wang, T., Shi, W., Zhang, S., Sullivan, D., Auwaerter, P. G., & Zhang, Y.
- Venue
- Emerging Microbes & Infections
- Publisher
- Informa UK Limited
- Published
- 2014-01
- Volume
- 3
- Issue
- 1
- Pages
- 1-8
- ISSN
- 2222-1751 (ISSN-L)
- OpenAlex
- W2095291804
- Cited by
- 113
- References
- 1
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.